Publications 2024

Hektoen HH, Tsuruda KM, Fjellbirkeland L, Nilssen Y, Brustugun OT, Andreassen BK (2024)
Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study
Br J Cancer, 132 (1), 93-102
DOI 10.1038/s41416-024-02895-1, PubMed 39489879

Publications 2023

Robsahm TE, Tsuruda KM, Hektoen HH, Storås AH, Cook MB, Hurwitz LM, Langseth H (2023)
Applying recommended definition of aggressive prostate cancer: a validation study using high-quality data from the Cancer Registry of Norway
Acta Oncol, 62 (1), 8-14
DOI 10.1080/0284186X.2023.2175331, PubMed 36762472

Publications 2021

Andreassen BK, Hektoen HH, Axcrona K, Langseth H, Stenehjem JS, Robsahm TE (2021)
Prediagnostic Serum-25 Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort: Answer to a Short Comment [Response to Letter]
Clin Epidemiol, 13, 1061-1062
DOI 10.2147/CLEP.S345565, PubMed 34803404

Hektoen HH, Gislefoss RE, Stenehjem JS, Langseth H, Axcrona K, Mondul AM, Robsahm TE, Andreassen BK (2021)
Prediagnostic Serum 25-Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort
Clin Epidemiol, 13, 801-811
DOI 10.2147/CLEP.S319620, PubMed 34548821

Hektoen HH, Robsahm TE, Stenehjem JS, Axcrona K, Babigumira R, Mondul AM, Gislefoss RE, Andreassen BK (2021)
Vitamin D and Vitamin D-binding protein and risk of bladder cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort
Cancer Med, 10 (12), 4107-4116
DOI 10.1002/cam4.3960, PubMed 34080787

Publications 2020

Hektoen HH, Robsahm TE, Andreassen BK, Stenehjem JS, Axcrona K, Mondul A, Gislefoss RE (2020)
Lifestyle associated factors and risk of urinary bladder cancer: A prospective cohort study from Norway
Cancer Med, 9 (12), 4420-4432
DOI 10.1002/cam4.3060, PubMed 32319230

Publications 2018

Gislefoss RE, Stenehjem JS, Hektoen HH, Andreassen BK, Langseth H, Axcrona K, Weiderpass E, Mondul A, Robsahm TE (2018)
Vitamin D, obesity and leptin in relation to bladder cancer incidence and survival: prospective protocol study
BMJ Open, 8 (3), e019309
DOI 10.1136/bmjopen-2017-019309, PubMed 29602840

Publications 2016

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
Radiother Oncol, 119 (3), 505-11
DOI 10.1016/j.radonc.2016.02.020, PubMed 26968754

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH (2016)
Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
BMC Cancer, 16, 536
DOI 10.1186/s12885-016-2601-x, PubMed 27461255

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH (2016)
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
Oncotarget, 7 (23), 34907-17
DOI 10.18632/oncotarget.8995, PubMed 27145458

Publications 2015

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH (2015)
Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
BMC Cancer, 15, 543
DOI 10.1186/s12885-015-1557-6, PubMed 26205955

Hektoen HH, Ree AH, Redalen KR, Flatmark K (2015)
Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells
J Enzyme Inhib Med Chem, 31 (5), 779-86
DOI 10.3109/14756366.2015.1069286, PubMed 26244271

Publications 2012

Hak S, Helgesen E, Hektoen HH, Huuse EM, Jarzyna PA, Mulder WJ, Haraldseth O, Davies Cde L (2012)
The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in vivo by dual modality imaging
ACS Nano, 6 (6), 5648-58
DOI 10.1021/nn301630n, PubMed 22671719

Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K (2012)
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
Radiat Oncol, 7, 165
DOI 10.1186/1748-717X-7-165, PubMed 23017053